These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30337096)

  • 1. Response to anti-VEGF therapy in macular oedema secondary to acute retinal necrosis.
    Sánchez Ramón A; Piñón Mosquera R; Mendieta Rasos N
    Arch Soc Esp Oftalmol (Engl Ed); 2019 Jan; 94(1):41-44. PubMed ID: 30337096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aflibercept in the management of acute retinal necrosis syndrome-related macular edema.
    Ortega-Evangelio L; Navarrete-Sanchis J; Williams BK; Tomás-Torrent JM
    Eur J Ophthalmol; 2018 Mar; 28(2):259-261. PubMed ID: 28967076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Mitry D; Bunce C; Charteris D
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis.
    Zhou S; Gao J; Xu X
    Clin Exp Ophthalmol; 2014; 42(7):637-49. PubMed ID: 24330277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.
    Papakostas TD; Lim L; van Zyl T; Miller JB; Modjtahedi BS; Andreoli CM; Wu D; Young LH; Kim IK; Vavvas DG; Esmaili DD; Husain D; Eliott D; Kim LA
    Eye (Lond); 2016 Jan; 30(1):79-84. PubMed ID: 26449196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endophthalmitis Rates after Bilateral Same-Day Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Borkar DS; Obeid A; Su DC; Storey PP; Gao X; Regillo CD; Kaiser RS; Garg SJ; Hsu J;
    Am J Ophthalmol; 2018 Oct; 194():1-6. PubMed ID: 29981738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.
    Eadie JA; Ip MS; Kulkarni AD
    Retina; 2014 Dec; 34(12):2439-43. PubMed ID: 24999721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion.
    Babiuch AS; Han M; Conti FF; Wai K; Silva FQ; Singh RP
    JAMA Ophthalmol; 2019 Jan; 137(1):38-46. PubMed ID: 30286219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
    Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
    Shimura M; Kitano S; Muramatsu D; Fukushima H; Takamura Y; Matsumoto M; Kokado M; Kogo J; Sasaki M; Morizane Y; Kotake O; Koto T; Sonoda S; Hirano T; Ishikawa H; Mitamura Y; Okamoto F; Kinoshita T; Kimura K; Sugimoto M; Yamashiro K; Suzuki Y; Hikichi T; Washio N; Sato T; Ohkoshi K; Tsujinaka H; Kusuhara S; Kondo M; Takagi H; Murata T; Sakamoto T;
    Br J Ophthalmol; 2020 Sep; 104(9):1209-1215. PubMed ID: 31784500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegaptanib sodium for acute retinal necrosis-induced macular oedema.
    Amselem L; Diaz-Llopis M; Cervera E; Salom D; Huste F; Montero J
    Acta Ophthalmol; 2010 Mar; 88(2):e42-3. PubMed ID: 18937824
    [No Abstract]   [Full Text] [Related]  

  • 13. Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis.
    Spooner K; Hong T; Fraser-Bell S; Chang AA
    Ophthalmologica; 2019; 242(3):163-177. PubMed ID: 31158837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion.
    Kida T; Tsujikawa A; Muraoka Y; Harino S; Osaka R; Murakami T; Ooto S; Suzuma K; Morishita S; Fukumoto M; Suzuki H; Ikeda T
    Ophthalmologica; 2016; 235(2):106-13. PubMed ID: 26800210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Switching to eylea in macular edema due to retinal vascular diseases].
    Pascual-Camps I; Hernández-Martínez P; Ruiz J; Dolz-Marco R; Cuellar MJ; Gallego-Pinazo R
    Arch Soc Esp Oftalmol; 2015 Jan; 90(1):48. PubMed ID: 25200895
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical real-world results of switching treatment from ranibizumab to aflibercept in patients with diabetic macular oedema.
    Konidaris VE; Tsaousis KT; Al-Hubeshy Z; Pieri K; Deane J; Empeslidis T
    Eye (Lond); 2017 Nov; 31(11):1629-1630. PubMed ID: 28622326
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.
    Cohen MN; Houston SK; Juhn A; Ho AC; Regillo CD; Vander J; Chiang A
    Can J Ophthalmol; 2016 Oct; 51(5):342-347. PubMed ID: 27769324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes.
    Ciulla TA; Pollack JS; Williams DF
    Br J Ophthalmol; 2021 Feb; 105(2):216-221. PubMed ID: 32265201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canadian preference and trends survey results for anti-VEGF treatment of macular edema.
    Rayat JS; Grewal PS; Whelan J; Tennant MT; Choudhry N
    Can J Ophthalmol; 2016 Jun; 51(3):233-7. PubMed ID: 27316276
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.